Skip to main content
Clinical Trials/NL-OMON31753
NL-OMON31753
Completed
Phase 4

A multi-center, randomized, controlled trial with programmed introduction of Sirolimus-based, Calcineurin inhibitor free immunosuppression in recipients of non-heart-beating donor kidney grafts. - PRINS study

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
kidney transplant function
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
100
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age: at least 18 years
  • Acceptable renal function (eGFR Nankivell \> 30 ml/min, proteinuria \< 1\.0 g/day)
  • 3 \- 4 months post renal transplantation with non\-heart\-beating donor graft

Exclusion Criteria

  • Banff grade \> 2 acute or vascular rejection at any time during this transplant pre\-randomization
  • Multiple organ transplants (i.e., prior or concurrent transplantation of any organs other than renal transplant)..
  • Evidence of active systemic or localized major infection.
  • Planned use of agents with a known interaction with any of the following: sirolimus or its derivatives, macrolide antibiotics, corticosteroids, tacrolimus, or IMPDH inhibitor.
  • Immunosuppressive therapies other than those described above
  • Subjects with a screening/baseline total white blood cell count \< 2,000/mm3 or ANC \< 1000, platelet count \< 100,000/mm3\.
  • Fasting triglycerides \> 400 mg/dL (\> 4\.5 mmol/L) or fasting total cholesterol \> 300 mg/dL (\> 7\.8 mmol/L) despite optimal lipid\-lowering therapy.
  • Subjects who are known to be HIV positive and/or subjects with active Hepatitis B or active Hepatitis C.

Outcomes

Primary Outcomes

Not specified

Similar Trials